0.04
-0.0008(-1.81%)
Currency In USD
| Previous Close | 0.04 |
| Open | 0.04 |
| Day High | 0.05 |
| Day Low | 0.04 |
| 52-Week High | 0.05 |
| 52-Week Low | 0.04 |
| Volume | 7,793 |
| Average Volume | 35,543.74 |
| Market Cap | 293,104 |
| PE | -0.03 |
| EPS | -1.73 |
| Moving Average 50 Days | 0.06 |
| Moving Average 200 Days | 0.06 |
| Change | -0 |
Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Feb 17, 2026 1:00 PM GMT
KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private i
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
GlobeNewswire Inc.
Nov 10, 2025 1:00 PM GMT
Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate’s transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a $6 million financing KANSAS CI
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
GlobeNewswire Inc.
Oct 28, 2025 12:00 PM GMT
Once-daily formulation of dexmethylphenidate achieved primary endpoint (p < 0.001) with consistent symptom relief up to 12 hours post-doseKANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical compan